Context Therapeutics (CNTX) News Today $0.60 -0.12 (-16.68%) Closing price 04:00 PM EasternExtended Trading$0.61 +0.01 (+2.49%) As of 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Zacks.com featured highlights include Context Therapeutics, Blue Bird, Dycom Industries and LeidosApril 4 at 11:09 AM | finance.yahoo.comContext Therapeutics to Participate in Upcoming Investor ConferencesApril 1 at 7:30 AM | globenewswire.comContext Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Buy" from AnalystsMarch 29, 2025 | americanbankingnews.comContext Therapeutics to Showcase CT-95 Data at AACR 2025March 28, 2025 | msn.comContext Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025March 26, 2025 | globenewswire.comWhat is HC Wainwright's Estimate for CNTX Q3 Earnings?March 25, 2025 | americanbankingnews.comContext Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Rating of "Buy" from AnalystsContext Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) has earned an average rating of "Buy" from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recMarch 24, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for CNTX Q3 Earnings?Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Equities research analysts at HC Wainwright issued their Q3 2025 earnings estimates for shares of Context Therapeutics in a research report issued on Friday, March 21st. HC Wainwright analyst E. Bodnar anticipates that the company will postMarch 24, 2025 | marketbeat.comPiper Sandler Sticks to Their Buy Rating for Context Therapeutics (CNTX)March 23, 2025 | markets.businessinsider.comContext Therapeutics Reports 2024 Results and Outlines Clinical AdvancementsMarch 22, 2025 | msn.comCompanies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In GrowthMarch 22, 2025 | finance.yahoo.comContext Therapeutics (NASDAQ:CNTX) Issues Quarterly Earnings ResultsContext Therapeutics (NASDAQ:CNTX - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.05) by $0.01.March 22, 2025 | marketbeat.comContext Therapeutics (NASDAQ:CNTX) Earns "Buy" Rating from D. Boral CapitalD. Boral Capital reiterated a "buy" rating and issued a $9.00 target price on shares of Context Therapeutics in a research report on Friday.March 22, 2025 | marketbeat.comContext Therapeutics (NASDAQ:CNTX) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $5.00 price target on shares of Context Therapeutics in a report on Friday.March 22, 2025 | marketbeat.comContext Therapeutics Inc. Doses First Patient in Phase 1 Trial of CTIM-76 and Reports Strong Financial Position Transitioning into 2025March 20, 2025 | quiverquant.comContext Therapeutics Reports Full Year 2024 Operating and Financial ResultsMarch 20, 2025 | globenewswire.comContext Therapeutics (CNTX) to Release Earnings on ThursdayContext Therapeutics (NASDAQ:CNTX) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.March 13, 2025 | marketbeat.comContext Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Buy" from BrokeragesShares of Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) have earned an average recommendation of "Buy" from the seven ratings firms that are presently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation and one has given aFebruary 27, 2025 | marketbeat.comContext Therapeutics Inc.: Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 25, 2025 | finanznachrichten.deContext Therapeutics (NASDAQ:CNTX) Shares Up 2.1% - Time to Buy?Context Therapeutics (NASDAQ:CNTX) Shares Up 2.1% - Should You Buy?February 25, 2025 | marketbeat.comContext Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 24, 2025 | globenewswire.comContext Therapeutics to Showcase at Top 2025 Investor ConferencesFebruary 22, 2025 | msn.comContext Therapeutics to Participate in Upcoming Investor ConferencesFebruary 19, 2025 | globenewswire.comCentrexion stock hits 52-week low at $0.79 amid market challengesFebruary 11, 2025 | msn.comContext Therapeutics Inc. (NASDAQ:CNTX) Given Average Rating of "Buy" by BrokeragesShares of Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) have received a consensus recommendation of "Buy" from the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has issued a stFebruary 2, 2025 | marketbeat.comFranklin Resources Inc. Acquires Additional Shares in Context Therapeutics Inc.January 27, 2025 | gurufocus.comBreakthrough in Cancer Treatment? Context Therapeutics Launches Phase 1 Trial for CLDN6-Targeted TherapyJanuary 18, 2025 | msn.comContext Therapeutics Inc. (NASDAQ:CNTX) Short Interest UpdateContext Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totalling 1,530,000 shares, an increase of 55.1% from the December 15th total of 986,300 shares. Based on an average daily volume of 501,500 shares, the short-interest ratio is presently 3.1 days. Currently, 2.6% of the shares of the stock are sold short.January 17, 2025 | marketbeat.comContext Therapeutics Welcomes Andy Pasternak as New Chairman of the BoardJanuary 17, 2025 | msn.comContext Therapeutics Inc.: Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76January 15, 2025 | finanznachrichten.deD. Boral Capital Reaffirms Buy Rating for Context Therapeutics (NASDAQ:CNTX)D. Boral Capital restated a "buy" rating and issued a $9.00 price objective on shares of Context Therapeutics in a research report on Wednesday.January 15, 2025 | marketbeat.comContext doses first patient in Phase 1 clinical trial evaluating CTIM-76January 14, 2025 | markets.businessinsider.comContext Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76January 14, 2025 | globenewswire.comContext Therapeutics Appoints Andy Pasternak As Board ChairmanJanuary 13, 2025 | markets.businessinsider.comContext Therapeutics Inc. Appoints Andy Pasternak as Chairman of the Board to Drive Company's Growth in T Cell Engager DevelopmentJanuary 13, 2025 | quiverquant.comContext Therapeutics Appoints Andy Pasternak as Chairman of the Board of DirectorsJanuary 13, 2025 | globenewswire.comJMP Securities Initiates Coverage of Context Therapeutics (CNTX) with Market Outperform RecommendationJanuary 9, 2025 | msn.comContext Therapeutics (NASDAQ:CNTX) Upgraded to Strong-Buy at Citizens JmpCitizens Jmp upgraded Context Therapeutics to a "strong-buy" rating in a report on Wednesday.January 9, 2025 | marketbeat.comInnovative Growth Potential: Silvan Tuerkcan’s Buy Rating on Context TherapeuticsJanuary 8, 2025 | markets.businessinsider.comContext Therapeutics (NASDAQ:CNTX) Earns Outperform Rating from Analysts at JMP SecuritiesJMP Securities began coverage on Context Therapeutics in a report on Wednesday. They issued an "outperform" rating and a $4.00 target price for the company.January 8, 2025 | marketbeat.comContext Therapeutics (NASDAQ: CNTX)January 7, 2025 | fool.comContext Therapeutics Inc. (NASDAQ:CNTX) Short Interest Up 22.9% in DecemberContext Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 986,300 shares, a growth of 22.9% from the November 30th total of 802,800 shares. Based on an average trading volume of 525,700 shares, the days-to-cover ratio is presently 1.9 days. Approximately 1.7% of the shares of the company are short sold.December 31, 2024 | marketbeat.comFranklin Resources Inc. Invests $3.69 Million in Context Therapeutics Inc. (NASDAQ:CNTX)Franklin Resources Inc. bought a new stake in Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 1,853,988 shares of the company's stock, valued at approximately $3,6December 25, 2024 | marketbeat.comContext Therapeutics Secures Funding for Cancer Therapy PipelineDecember 2, 2024 | markets.businessinsider.comContext Therapeutics Inc. (NASDAQ:CNTX) Sees Significant Decrease in Short InterestContext Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) saw a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 879,600 shares, a decrease of 13.8% from the October 31st total of 1,020,000 shares. Currently, 1.5% of the company's shares are short sold. Based on an average daily volume of 278,800 shares, the days-to-cover ratio is currently 3.2 days.December 1, 2024 | marketbeat.comContext Therapeutics Inc. (NASDAQ:CNTX) Position Reduced by Great Point Partners LLCGreat Point Partners LLC trimmed its holdings in shares of Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) by 6.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,934,982 shares of the company's stock aNovember 27, 2024 | marketbeat.comD. Boral Capital Initiates Coverage of Context Therapeutics (CNTX) with Buy RecommendationNovember 26, 2024 | msn.comContext Therapeutics (NASDAQ:CNTX) Coverage Initiated at D. Boral CapitalD. Boral Capital began coverage on shares of Context Therapeutics in a research report on Monday. They set a "buy" rating and a $9.00 price target for the company.November 25, 2024 | marketbeat.comContext Therapeutics: Strategic Developments and Financial OutlookNovember 22, 2024 | markets.businessinsider.comPromising Preclinical Data and Strategic Trial Design Support Buy Rating for Context TherapeuticsNovember 12, 2024 | markets.businessinsider.com Remove Ads Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTX Media Mentions By Week CNTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CNTX News Sentiment▼0.200.61▲Average Medical News Sentiment CNTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CNTX Articles This Week▼32▲CNTX Articles Average Week Remove Ads Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DSGN News HUMA News ANNX News CRDF News INMB News OCGN News CRVS News ELDN News FHTX News INBX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CNTX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredWall St. Icon: Looming Financial Tsunami Could Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event could hit the America...InvestorPlace | SponsoredControversial opinion: Volume isn't enough.Don’t be fooled by volume alone — it's just one piece of the trading puzzle. High demand doesn’t matter if sup...MillPub | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CNTX Stock Free CNTX Stock Alerts